Original Articles
22 January 2025
Early Access
https://doi.org/10.4081/reumatismo.2025.1744

Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
IgG4-related disease, SARS-CoV-2, COVID-19, vaccination
1015
Views
250
Downloads

Authors

Linda Mastromanno
https://orcid.org/0009-0001-3114-8791
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Federico Giardina
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Angelica Gattamelata
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Serena Colafrancesco
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Simona Truglia
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Francesca Romana Spinelli
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Edoardo Simoncelli
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Bruno Lucchino
Rheumatology Unit, ASST FBF Sacco, Milan, Italy.
Fabrizio Conti
fabrizio.conti@uniroma1.it
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Roberta Priori
https://orcid.org/0000-0002-6695-1445
Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome; Unicamillus, Saint Camillus International University of Health Sciences, Rome, Italy.

Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients.

Methods. Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC).

Results. 20 patients and 40 HC were enrolled. In the patient’s cohort, 90% were vaccinated with at least one dose; among them, 9 reported AEs: 44.4% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 13 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported.

Conclusions. Results from our study indicate a good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nat Rev Rheumatol 2020; 16: 702-14. DOI: https://doi.org/10.1038/s41584-020-0500-7
Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, et al. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: results from the RECORDER project. Rheumatology 2022; 61: 3161-71. DOI: https://doi.org/10.1093/rheumatology/keab794
Chen Y, Dong Y, Cai S, Ye C, Dong L. Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China. Semin Arthritis Rheum 2020; 50: 559-63. DOI: https://doi.org/10.1016/j.semarthrit.2020.04.015
Tang RSY, Sattayalertyanyong O, Kuo YT, Park KH, Anastassiades C, Ligresti D, et al. Impact of COVID-19 infection and vaccination in pancreatobiliary IgG4-related disease patients: an international multicenter study. J Gastroenterol Hepatol 2023; 38: 584-9. DOI: https://doi.org/10.1111/jgh.16100
Ramirez GA, Lanzillotta M, Ebbo M, Fernandez-Codina A, Mancuso G, Orozco-Galvez O, et al. Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study. Rheumatology 2022; 61: e109-11. DOI: https://doi.org/10.1093/rheumatology/keab930
Umehara H, Okazaki K, Kawa S, Takahashi H, Goto H, Matsui S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021; 31: 529-33. DOI: https://doi.org/10.1080/14397595.2020.1859710
Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis 2022; 81: 1628-39. DOI: https://doi.org/10.1136/annrheumdis-2021-222006
Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M, et al. SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis 2021; 80: 953-4. DOI: https://doi.org/10.1136/annrheumdis-2021-220059
Simoncelli E, Conticini E, Colafrancesco S, Gattamelata A, Spinelli FR, Garufi C, et al. Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis. Clin Exper Rheumatol 2023; 41: 922-7. DOI: https://doi.org/10.55563/clinexprheumatol/if8nka
Inanc N, Kostov B, Priori R, Flores-Chavez A, Carubbi F, Szántó A, et al; Sjögren Big Data Consortium. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome. Clin Exp Rheumatol 2022; 40: 2290-7. DOI: https://doi.org/10.55563/clinexprheumatol/dt6klo
Barbhaiya M, Levine JM, Siegel CH, Bykerk VP, Jannat-Khah D, Mandl LA. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol 2022; 41: 1619-22. DOI: https://doi.org/10.1007/s10067-021-05963-6
Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis 2022; 81: 695-709. DOI: https://doi.org/10.1136/annrheumdis-2021-221490
Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, et al. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open 2022; 8: e002417. DOI: https://doi.org/10.1136/rmdopen-2022-002417
Aochi S, Uehara M, Yamamoto M. IgG4-related disease emerging after COVID-19 mRNA vaccination: a case report. Intern Med 2023; 62: 1547-51. DOI: https://doi.org/10.2169/internalmedicine.1125-22
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80: 930-42. DOI: https://doi.org/10.1136/annrheumdis-2020-219498
Armağan B, Konak HE, Özdemir B, Apaydın H, Atalar E, Akyüz Dağlı P, et al. COVID-19 disease frequency, risk factors, and re-infection rates in patients with autoimmune rheumatic disease receiving rituximab. Int J Rheum Dis 2023; 26: 930-7. DOI: https://doi.org/10.1111/1756-185X.14676
Bijlsma JW. EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis 2021; 80: 411-2. DOI: https://doi.org/10.1136/annrheumdis-2020-219773

How to Cite



Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease. (2025). Reumatismo. https://doi.org/10.4081/reumatismo.2025.1744
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.